Promega Corporation

Promega Corporation is a privately held global leader in providing innovative solutions and technical support to the life sciences industry. Founded in 1978 by William A. Linton, who continues to serve as Chairman and CEO, the company is headquartered in Madison, Wisconsin, USA. Promega's mission is to be the most responsive supplier of biological reagents and reagent systems for research and applied technology applications worldwide, with a broader vision of contributing to science and improving life for all global citizens.

The company's extensive portfolio comprises over 4,000 products, including enzymes, reagents, assay kits, instruments, and integrated systems. These offerings support a wide range of scientific work in genomics, protein analysis and expression, cellular analysis, drug discovery, and genetic identity. Key product lines include PowerPlex® STR human identification systems, NanoLuc® luciferase-based reporter technology, Maxwell® instruments for nucleic acid extraction, and GloMax® microplate readers. Promega serves diverse market segments, including academic and government research, pharmaceutical and biotech companies, forensic laboratories, clinical and diagnostics labs, and agricultural/environmental testing.

In recent news, Promega Corporation was recognized as a 2025 Best-in-Class Employer by Gallagher for its excellence in employee wellbeing and benefits. The company has also achieved 100% renewable electricity across its global operations. Promega continues to innovate, launching new products such as the 24-Capillary Spectrum CE System and Paradyme™ 27GY STR System in 2026 for forensic DNA analysis. Furthermore, Promega has partnered with Merck to co-develop novel technologies for drug screening and discovery, particularly focusing on 3D cell cultures. The company played a significant role in the COVID-19 pandemic response by increasing manufacturing tenfold to meet demand for critical reagents.